Epigenetics in heart failure phenotypes

BBA Clinical

Volumn 6, Issue , 2016, Pages 31-37

  Berezin, Alexander ^a  

^a ZAPORIZHZHIA STATE MEDICAL UNIVERSITY   (Ukraine)

Author keywords

Chromatin remodeling; Epigenetic modifications; Heart failure with preserved ejection fraction; Heart failure with reduced ejection fraction

Indexed keywords

HISTONE H3; MICRORNA; MYOSIN HEAVY CHAIN ALPHA; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; TRANSFORMING GROWTH FACTOR BETA;

CHROMATIN ASSEMBLY AND DISASSEMBLY; DEACETYLATION; DNA METHYLATION; EPIGENETICS; GENE EXPRESSION; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE FIBROSIS; HEART VENTRICLE HYPERTROPHY; HISTONE MODIFICATION; HUMAN; NONHUMAN; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW;

EID: 84973375752     PISSN: 22146474     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbacli.2016.05.005     Document Type: Review

References (109)

1. Mozaffarian D., Benjamin E.J., Go A.S., Arnett D.K., Blaha M.J., Cushman M., et al. American Heart Association statistics committee and stroke statistics subcommittee. Executive summary: heart disease and stroke statistics-2016 update: A report from the American Heart Association. Circulation 2016, 133(4):447-454.
2. Güder G., Gelbrich G., Edelmann F., Wachter R., Pieske B., Pankuweit S., Competence Network Heart Failure Germany, et al. Reverse epidemiology in different stages of heart failure. Int. J. Cardiol. 2015, 184:216-224.
3. van Riet E.E., Hoes A.W., Wagenaar K.P., Limburg A., Landman M.A., Rutten F.H. Epidemiology of heart failure: the prevalence of heart failure and ventricular dysfunction in older adults over time. A systematic review. Eur. J. Heart Fail. 2016, 18(3):242-252.
4. Edelmann F. Epidemiology and prognosis of heart failure. Herz 2015, 40(2):176-184.
5. Jorge A.L., Rosa M.L., Martins W.A., Correia D.M., Fernandes L.C., Costa J.A., et al. The prevalence of stages of heart failure in primary care: a population-based study. J. Card. Fail. 2016, 22(2):153-157.
6. van Veldhuisen D.J., Linssen G.C., Jaarsma T., van Gilst W.H., Hoes A.W., Tijssen J.G., et al. B-type natriuretic peptide and prognosis in heart failure patients with preserved and reduced ejection fraction. J. Am. Coll. Cardiol. 2013, 61(14):1498-1506.
7. Bettencourt P., Azevedo A., Fonseca L., Araújo J.P., Ferreira S., Almeida R., et al. Prognosis of decompensated heart failure patients with preserved systolic function is predicted by NT-proBNP variations during hospitalization. Int. J. Cardiol. 2007, 117(1):75-79.
8. Kang S.H., Park J.J., Choi D.J., Yoon C.H., Oh I.Y., Kang S.M., KorHF Registry, et al. Prognostic value of NT-proBNP in heart failure with preserved versus reduced EF. Heart 2015, 101(23):1881-1888.
9. Nichols G.A., Reynolds K., Kimes T.M., Rosales A.G., Chan W.W. Comparison of risk of re-hospitalization, all-cause mortality, and medical care resource utilization in patients with heart failure and preserved versus reduced ejection fraction. Am. J. Cardiol. 2015, 116(7):1088-1092.
10. McMurray J.J., Adamopoulos S., Anker S.D., Auricchio A., Böhm M., Dickstein K., ESC Committee for Practice Guidelines, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur. Heart J. 2012, 33(14):1787-1847.
11. Yancy C.W., Jessup M., Bozkurt B., Butler J., Casey D.E., Drazner M.H., American College of Cardiology Foundation, American Heart Association Task Force on Practice Guidelines, et al. AHA/AHA guideline for the management of heart failure: report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J. Am. Coll. Cardiol. 2013, 62(16):e147-e239.
12. Fischer C., Steyerberg E.W., Fonarow G.C., Ganiats T.G., Lingsma H.F. A systematic review and meta-analysis on the association between quality of hospital care and readmission rates in patients with heart failure. Am. Heart J. 2015, 170(5). (1005-1017.e2).
13. Berezin A.E. Predicting heart failure phenotypes using cardiac biomarkers: hype and hope. J. Dis. Markers 2015, 2(4):1035-1041.
14. Berezin A.E. Prognostication in different heart failure phenotypes: the role of circulating biomarkers. J. Circulating Biomark. 2016, 5. (ahead of print). 10.5772/62797.
15. Napoli C., Grimaldi V., De Pascale M.R., Sommese L., Infante T., Soricelli A. Novel epigenetic-based therapies useful in cardiovascular medicine. World J. Cardiol. 2016, 8(2):211-219.
16. Di Salvo T.G., Haldar S.M. Epigenetic mechanisms in heart failure pathogenesis. Circ. Heart Fail. 2014, 7(5):850-863.
17. Mollova M.Y., Katus H.A., Backs J. Regulation of CaMKII signaling in cardiovascular disease. Front. Pharmacol. 2015, 6:178.
18. Mann J.R. Epigenetics and memigenetics. Cell. Mol. Life Sci. 2014, 71(7):1117-1122.
19. Roloff T.C., Nuber U.A. Chromatin, epigenetics and stem cells. Eur. J. Cell Biol. 2005, 84(2-3):123-135.
20. Romanoski C.E., Glass C.K., Stunnenberg H.G., Wilson L., Almouzni G. Epigenomics: roadmap for regulation. Nature 2015, 518(7539):314-316.
21. Berger S.L., Kouzarides T., Shiekhattar R., Shilatifard A. An operational definition of epigenetics. Genes Dev. 2009, 23(7):781-783.
22. Cao Y., Lu L., Liu M., Li X.C., Sun R.R., Zheng Y., Zhang P.Y. Impact of epigenetics in the management of cardiovascular disease: a review. Eur. Rev. Med. Pharmacol. Sci. 2014, 18(20):3097-3104.
23. Bronner C., Chataigneau T., Schini-Kerth V.B., Landry Y. The "Epigenetic Code Replication Machinery", ECREM: a promising drugable target of the epigenetic cell memory. Curr. Med. Chem. 2007, 14(25):2629-2641.
24. Swaminathan V., Reddy B.A., Ruthrotha Selvi B., Sukanya M.S., Kundu T.K. Small molecule modulators in epigenetics: implications in gene expression and therapeutics. Subcell. Biochem. 2007, 41:397-428.
25. Marín-García J., Akhmedov A.T. Epigenetics of the failing heart. Heart Fail. Rev. 2015, 20(4):435-459.
26. Yang J., Xu W.W., Hu S.J. Heart failure: advanced development in genetics and epigenetics. Biomed Res. Int. 2015, 2015:352734.
27. Schiano C., Vietri M.T., Grimaldi V., Picascia A., Pascale M.R., Napoli C. Epigenetic-related therapeutic challenges in cardiovascular disease. Trends Pharmacol. Sci. 2015, 36(4):226-235.
28. Berezin A.E. Circulating cell-free mitochondrial DNA as biomarker of cardiovascular risk: new challenges of old findings. Angiology 2015, 3:161-163.
29. Berezin A. Metabolic memory phenomenon in diabetes mellitus: Achieving and perspectives. Diabetes Metab. Syndr. 2016, (Epub ahead of print). 10.1016/j.dsx.2016.03.016.
30. Berezin A.E. Impaired phenotype of circulating endothelial-derived microparticles: novel marker of cardiovascular risk. J. Cardiol. Ther. 2015, 2(4):273-278.
31. Berezin A.E. Endothelial derived micro particles: biomarkers for heart failure diagnosis and management. J. Clin. Trials Cardiol. 2015, 2(3):1-3.
32. Berezin A., Kremzer A., Berezina T., Yu M., Gromenko O. Pattern of endothelial progenitor cells and apoptotic endothelial cell-derived microparticles in chronic heart failure patients with preserved and reduced left ventricular ejection fraction. EBioMedicine 2016, 4:86-94. 10.1016/j.ebiom.2016.01.018.
33. Berezin A., Kremzer A., Berezina T., Martovotskaya Y. Pattern of circulating microparticles in chronic heart failure patients with metabolic syndrome: relevance to neurohumoral and inflammatory activation. BBA Clin. 2015, 4:69-75.
34. Duygu B., Poels E.M., da Costa Martins P.A. Genetics and epigenetics of arrhythmia and heart failure. Front. Genet. 2013, 4:219. 10.3389/fgene.2013.00219.
35. Papait R., Cattaneo P., Kunderfranco P., Greco C., Carullo P., Guffanti A., et al. Genome-wide analysis of histone marks identifying an epigenetic signature of promoters and enhancers underlying cardiac hypertrophy. Proc. Natl. Acad. Sci. U. S. A. 2013, 110(50):20164-20169.
36. Suganuma T., Workman J.L. Signals and combinatorial functions of histone modifications. Annu. Rev. Biochem. 2011, 80:473-499.
37. Tao H., Yang J.J., Shi K.H. Non-coding RNAs as direct and indirect modulators of epigenetic mechanism regulation of cardiac fibrosis. Expert Opin. Ther. Targets 2015, 19(5):707-716.
38. Piran S., Liu P., Morales A., Hershberger R.E. Where genome meets phenome: rationale for integrating genetic and protein biomarkers in the diagnosis and management of dilated cardiomyopathy and heart failure. J. Am. Coll. Cardiol. 2012, 60(4):283-289.
39. Maunakea A.K., Nagarajan R.P., Bilenky M., Ballinger T.J., D'Souza C., Fouse S.D., et al. Conserved role of intragenic DNA methylation in regulating alternative promoters. Nature 2010, 466(7303):253-257.
40. Movassagh M., Choy M.K., Knowles D.A., Cordeddu L., Haider S., Down T., et al. Distinct epigenomic features in end-stage failing human hearts. Circulation 2011, 124(22):2411-2422.
41. Watson C.J., Collier P., Tea I., Neary R., Watson J.A., Robinson C., et al. Hypoxia-induced epigenetic modifications are associated with cardiac tissue fibrosis and the development of a myofibroblast-like phenotype. Hum. Mol. Genet. 2014, 23(8):2176-2188.
42. Haider S., Cordeddu L., Robinson E., Movassagh M., Siggens L., Vujic A., Choy M.K., Goddard M., Lio P., Foo R. The landscape of DNA repeat elements in human heart failure. Genome Biol. 2012, 13(10):R90.
43. Jones P.A. The DNA methylation paradox. Trends Genet. 1999, 15(1):34-37.
44. Xiao D., Dasgupta C., Chen M., Zhang K., Buchholz J., Xu Z., Zhang L. Inhibition of DNA methylation reverses norepinephrine-induced cardiac hypertrophy in rats. Cardiovasc. Res. 2014, 101(3):373-382.
45. Haas J., Frese K.S., Park Y.J., Keller A., Vogel B., Lindroth A.M., et al. Alterations in cardiac DNA methylation in human dilated cardiomyopathy. EMBO Mol. Med. 2013, 5(3):413-429.
46. Konig A., Bode C., Bugger H. Diabetes mellitus and myocardial mitochondrial dysfunction: bench to bedside. Heart Fail. Clin. 2012, 8(4):551-561.
47. Chen H., Orozco L.D., Wang J., Rau C.D., Rubbi L., Ren S., et al. DNA methylation indicates susceptibility to isoproterenol-induced cardiac pathology and is associated with chromatin states. Circ. Res. 2016, 118(5):786-797.
48. Varga-Weisz P. Chromatin remodeling factors and DNA replication. Prog. Mol. Subcell. Biol. 2005, 38:1-30.
49. Clapier C.R., Cairns B.R. The biology of chromatin remodeling complexes. Annu. Rev. Biochem. 2009, 78:273-304.
50. Saha A., Wittmeyer J., Cairns B.R. Mechanisms for nucleosome movement by ATP-dependent chromatin remodeling complexes. Results Probl. Cell Differ. 2006, 41:127-148.
51. Lange M., Demajo S., Jain P., Di Croce L. Combinatorial assembly and function of chromatin regulatory complexes. Epigenomics 2011, 3(5):567-580.
52. Ho L., Crabtree G.R. Chromatin remodelling during development. Nature 2010, 463(7280):474-484.
53. Newell-Price J., Clark A.J., King P. DNA methylation and silencing of gene expression. Trends Endocrinol. Metab. 2000, 11(4):142-148.
54. Chodavarapu R.K., Feng S., Bernatavichute Y.V., Chen P.Y., Stroud H., Yu Y., et al. Relationship between nucleosome positioning and DNA methylation. Nature 2010, 466(7304):388-392.
55. Kunkel G.H., Chaturvedi P., Tyagi S.C. Resuscitation of a dead cardiomyocyte. Heart Fail. Rev. 2015, 20(6):709-719.
56. Kunkel G.H., Chaturvedi P., Tyagi S.C. Epigenetic revival of a dead cardiomyocyte through mitochondrial interventions. Biomol. Concepts 2015, 6(4):303-319.
57. Wiley M.M., Muthukumar V., Griffin T.M., Griffin C.T. SWI/SNF chromatin-remodeling enzymes Brahma-related gene 1 (BRG1) and Brahma (BRM) are dispensable in multiple models of postnatal angiogenesis but are required for vascular integrity in infant mice. J. Am. Heart Assoc. 2015, 4(4). (pii: e001972). 10.1161/JAHA.115.001972.
58. Marquez S.B., Thompson K.W., Lu L., Reisman D. Beyond mutations: additional mechanisms and implications of SWI/SNF complex inactivation. Front. Oncol. 2015, 4:372.
59. Bultman S.J., Holley D.W., de Ridder G., Pizzo S.V., Sidorova T.N., Murray K.T., et al. BRG1 and BRM SWI/SNF ATPases redundantly maintain cardiomyocyte homeostasis by regulating cardiomyocyte mitophagy and mitochondrial dynamics in vivo. Cardiovasc. Pathol. 2016, 25(3):258-269.
60. Kim S.Y., Morales C.R., Gillette T.G., Hill J.A. Epigenetic regulation in heart failure. Curr. Opin. Cardiol. 2016, (Epub ahead of print).
61. Zhang Y., Fatima N., Dufau M.L. Coordinated changes in DNA methylation and histone modifications regulate silencing/derepression of luteinizing hormone receptor gene transcription. Mol. Cell. Biol. 2005, 25(18):7929-7939.
62. Jenuwein T., Allis C.D. Translating the histone code. Science 2001, 293(5532):1074-1080.
63. Handy D.E., Castro R., Loscalzo J. Epigenetic modifications: basic mechanisms and role in cardiovascular disease. Circulation 2011, 123(19):2145-2156.
64. Margueron R., Reinberg D. Chromatin structure and the inheritance of epigenetic information. Nat. Rev. Genet. 2010, 11(4):285-296.
65. Robb G.B., Carson A.R., Tai S.C., Fish J.E., Singh S., Yamada T., et al. Post-transcriptional regulation of endothelial nitric-oxide synthase by an overlapping antisense mRNA transcript. J. Biol. Chem. 2004, 279(36):37982-37996.
66. Tai S.C., Robb G.B., Marsden P.A. Endothelial nitric oxide synthase: a new paradigm for gene regulation in the injured blood vessel. Arterioscler. Thromb. Vasc. Biol. 2004, 24(3):405-412.
67. Shi Y., Whetstine J.R. Dynamic regulation of histone lysine methylation by demethylases. Mol. Cell 2007, 25(1):1-14.
68. Kim G.H., Ryan J.J., Archer S.L. The role of redox signaling in epigenetics and cardiovascular disease. Antioxid. Redox Signal. 2013, 18(15):1920-1936.
69. Illi B., Ciarapica R., Capogrossi M.C. Chromatin methylation and cardiovascular aging. J. Mol. Cell. Cardiol. 2015, 83:21-31.
70. Berezin A. "Impaired immune phenotype" of endothelial cell-derived microparticles: the missed link between diabetes-related states and cardiovascular complications?. J. Data Min. Genomics Proteomics 2016, 7(2):195-197.
71. Ambros V. microRNAs: tiny regulators with great potential. Cell 2001, 107:823-826.
72. Thum T., Galuppo P., Wolf C., Fiedler J., Kneitz S., van Laake L.W., et al. MicroRNAs in the human heart: a clue to fetal gene reprogramming in heart failure. Circulation 2007, 116(3):258-267.
73. van Rooij E., Sutherland L.B., Liu N., Williams A.H., McAnally J., Gerard R.D., Richardson J.A., Olson E.N. A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:18255-18260.
74. Sayed D., Hong C., Chen I.Y., Lypowy J., Abdellatif M. MicroRNAs play an essential role in the development of cardiac hypertrophy. Circ. Res. 2007, 100:416-424.
75. Ikeda S., Kong S.W., Lu J., Bisping E., Zhang H., Allen P.D., Golub T.R., Pieske B., Pu W.T. Altered microRNA expression in human heart disease. Physiol. Genomics 2007, 31(3):367-373.
76. Sucharov C., Bristow M.R., Port J.D. miRNA expression in the failing human heart: functional correlates. J. Mol. Cell. Cardiol. 2008, 45(2):185-192.
77. Udali S., Guarini P., Moruzzi S., Choi S.W., Friso S. Cardiovascular epigenetics: from DNA methylation to microRNAs. Mol. Asp. Med. 2013, 34(4):883-901.
78. Grueter C.E., van Rooij E., Johnson B.A., DeLeon S.M., Sutherland L.B., Qi X., et al. A cardiac microRNA governs systemic energy homeostasis by regulation of MED13. Cell 2012, 149(3):671-683.
79. Ikeda S., He A., Kong S.W., Lu J., Bejar R., Bodyaket N., et al. MicroRNA-1 negatively regulates expression of the hypertrophy-associated calmodulin and Mef2a genes. Mol. Cell. Biol. 2009, 29(8):2193-2204.
80. Izumo S., Nadal-Ginard B., Mahdavi V. Protooncogene induction and reprogramming of cardiac gene expression produced by pressure overload. Proc. Natl. Acad. Sci. U. S. A. 1988, 85:339-343.
81. Bagnall R.D., Tsoutsman T., Shephard R.E., Ritchie W., Semsarian C. Global microRNA profiling of the mouse ventricles during development of severe hypertrophic cardiomyopathy and heart failure. PLoS One 2012, 7.
82. Guo C., Deng Y., Liu J., Qian L. Cardiomyocyte-specific role of miR-24 in promoting cell survival. J. Cell. Mol. Med. 2015, 19:103-112.
83. Wang J., Huang W., Xu R., Nie Y., Cao X., Meng J., et al. MicroRNA-24 regulates cardiac fibrosis after myocardial infarction. J. Cell. Mol. Med. 2012, 16:2150-2160.
84. Zhou Y., Deng L., Zhao D., Chen L., Yao Z., Guo X., et al. MicroRNA-503 promotes angiotensin II-induced cardiac fibrosis by targeting Apelin-13. J. Cell. Mol. Med. 2016, 20(3):495-505.
85. Thum T., Gross C., Fiedler J., Fischer T., Kissler S., Bussen M., et al. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature 2008, 456:980-984.
86. WS, Hill J.A., Olson E.N. Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:13027-13032.
87. Derda A.A., Thum S., Lorenzen J.M., Bavendiek U., Heineke J., Keyser B., et al. Blood-based microRNA signatures differentiate various forms of cardiac hypertrophy. Int. J. Cardiol. 2015, 196:115-122.
88. Chen S., Puthanveetil P., Feng B., Matkovich S.J., Dorn G.W., Chakrabarti S. Cardiac miR-133a overexpression prevents early cardiac fibrosis in diabetes. J. Cell. Mol. Med. 2014, 18(3):415-421.
89. Sen C.K. MicroRNAs as new maestro conducting the expanding symphony orchestra of regenerative and reparative medicine. Physiol. Genomics 2011, 43(10):517-520.
90. Hinkel R., Penzkofer D., Zuhlke S., Fischer A., Husada W., Xu Q.F., Baloch E., van Rooij E., Zeiher A.M., Kupatt C., Dimmeler S. Inhibition of microRNA-92a protects against ischemia/reperfusion injury in a large-animal model. Circulation 2013, 128:1066-1075.
91. Vegter E.L., van der Meer P., de Windt L.J., Pinto Y.M., Voors A.A. MicroRNAs in heart failure: from biomarker to target for therapy. Eur. J. Heart Fail. 2016, (Epub ahead of print). 10.1002/ejhf.495.
92. van Rooij E., Sutherland L.B., Thatcher J.E., DiMaio J.M., Naseem R.H., Marshall Ellis K.L., et al. Circulating microRNAs as candidate markers to distinguish heart failure in breathless patients. Eur. J. Heart Fail. 2013, 15:1138-1147.
93. Ovchinnikova E.S., Schmitter D., Vegter E.L., Ter Maaten J.M., Valente M.A., Liu L.C., et al. Signature of circulating microRNAs in patients with acute heart failure. Eur. J. Heart Fail. 2015, 10.1002/ejhf.332.
94. Corsten M.F., Dennert R., Jochems S., Kuznetsova T., Devaux Y., Hofstra L., et al. Circulating MicroRNA-208b and MicroRNA-499 reflect myocardial damage in cardiovascular disease. Circ. Cardiovasc. Genet. 2010, 3:499-506.
95. Qiang L., Hong L., Ningfu W., Huaihong C., Jing W. Expression of miR-126 and miR-508-5p in endothelial progenitor cells is associated with the prognosis of chronic heart failure patients. Int. J. Cardiol. 2013, 168:2082-2088.
96. Seronde M.F., Vausort M., Gayat E., Goretti E., Ng L.L., Squire I.B., GREAT network, et al. Circulating microRNAs and outcome in patients with acute heart failure. PLoS One 2015, 10(11).
97. Recchioni R., Marcheselli F., Antonicelli R., Lazzarini R., Mensà E., Testa R., et al. Physical activity and progenitor cell-mediated endothelial repair in chronic heart failure: is there a role for epigenetics?. Mech. Ageing Dev. Mar 24 2016, (pii: S0047-6374(16)30029-X, Epub ahead of print). 10.1016/j.mad.2016.03.008.
98. Suzuki T., Lyon A., Saggar R., Heaney L.M., Aizawa K., Cittadini A., et al. Biomarkers of acute cardiovascular and pulmonary diseases. Eur Heart J Acute Cardiovasc Care. 2016, [Epub ahead of print].
99. Berezin A. Impaired phenotype of endothelial cell-derived micro particles: the missed link in heart failure development?. Biomark. J. 2016, 2(2):14-19.
100. Napoli C., Grimaldi V., De Pascale M.R., Sommese L., Infante T., Soricelli A. Novel epigenetic-based therapies useful in cardiovascular medicine. World J. Cardiol. 2016, 8(2):211-219.
101. Aune S.E., Herr D.J., Kutz C.J., Menick D.R. Histone deacetylases exert class-specific roles in conditioning the brain and heart against acute ischemic injury. Front. Neurol. 2015, 6:145.
102. Ooi J.Y., Tuano N.K., Rafehi H., Gao X.M., Ziemann M., Du X.J., et al. HDAC inhibition attenuates cardiac hypertrophy by acetylation and deacetylation of target genes. Epigenetics 2015, 10(5):418-430.
103. Nural-Guvener H., Zakharova L., Feehery L., Sljukic S., Gaballa M. Anti-fibrotic effects of class I HDAC inhibitor, mocetinostat is associated with IL-6/Stat3 signaling in ischemic heart failure. Int. J. Mol. Sci. 2015, 16(5):11482-11499.
104. Montgomery R.L., Hullinger T.G., Semus H.M., Dickinson B.A., Seto A.G., Lynch J.M., et al. Therapeutic inhibition of miR-208a improves cardiac function and survival during heart failure. Circulation 2011, 124:1537-1547.
105. Zhang Y., Huang X.R., Wei L.H., Chung A.C., Yu C.M., Lan H.Y. miR-29b as a therapeutic agent for angiotensin II-induced cardiac fibrosis by targeting TGF-beta/Smad3 signaling. Mol. Ther. 2014, 22:974-985.
106. van Rooij E., Olson E.N. MicroRNA therapeutics for cardiovascular disease: opportunities and obstacles. Nat. Rev. Drug Discov. 2012, 11:860-872.
107. Voelter-Mahlknecht S. Epigenetic associations in relation to cardiovascular prevention and therapeutics. Clin. Epigenetics 2016, 8:4.
108. Crozatier B., Ventura-Clapier R. Inhibition of hypertrophy, per se, may not be a good therapeutic strategy in ventricular pressure overload: other approaches could be more beneficial. Circulation 2015, 131(16):1448-1457.
109. Berezin A. Progenitor endothelial cell dysfunction in heart failure: clinical implication and therapeutic target?. Transl. Med. (Sunnyvale) 2016, 6(3):176-177. 10.4172/2161-1025.1000176.